A study of the 3-year incidence of diabetic retinopathy in a French diabetic population seen at Lariboisière Hospital, Paris

Diabetes and Metabolism

Volumn 38, Issue 3, 2012, Pages 225-229

  Perol, J ^a   Balkau, B ^b   Guillausseau, P J ^a   Massin, P ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

Author keywords

Diabetic retinopathy; Incidence; OPHDIAT ; Risk factors; Screening

Indexed keywords

INSULIN;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETIC RETINOPATHY; DISEASE COURSE; DISEASE DURATION; FEMALE; FOLLOW UP; FRANCE; HUMAN; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; MORBIDITY; RETROSPECTIVE STUDY; RISK ASSESSMENT;

ALBUMINURIA; COHORT STUDIES; DIABETIC RETINOPATHY; DISEASE PROGRESSION; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PARIS; RETROSPECTIVE STUDIES; RISK FACTORS; TELEMEDICINE; TIME FACTORS;

EID: 84863499584     PISSN: 12623636     EISSN: 18781780     Source Type: Journal    
DOI: 10.1016/j.diabet.2012.01.001     Document Type: Article

References (21)

1. Franck R.N. Diabetic retinopathy. N Eng J Med 2004, 350:48-58.
2. Hovind P., Tarnow L., Rossing K., Rossing P., Eising S., Larsen N., et al. Decreasing incidence of severe diabetic microangiopathy in type-1 diabetes. Diabetes Care 2003, 26:1258-1264.
3. Klein R., Knudtson M.D., Lee K.E., Gangnon R., Klein B.E. The Wisconsin Epidemiologic study of diabetic retinopathy: XXII the twenty five years progression of retinopathy in persons with type 1 diabetes. Ophthalmology 2008, 115:1859-1868.
4. Agardh E., Agardh C.D., Hansson-Lunblad C. The five years incidence of blindness after introducing a screening program for early detection of treatable diabetic retinopathy. Diabetes Metab 1992, 10:555-559.
5. Kristinsson J.K., Hauksdottir H., Stefabsson E., Jonasson F., Gislason I. Active prevention in diabetic eye disease. Acta Ophthalmol Scand 1997, 75:249-254.
6. Ricci P., Blotière P.O., Weill A., Simon D., Tuppin P., Ricordeau P., et al. Treated diabetes: which trends between 2000 and 2009 in France. Bull Epidemiol Hebdomadaire 2010, 42-43:425-431.
7. ®: a telemedical network to screen for diabetic retinopathy in Ile-de-France. Diabetes Metab 2008, 34:227-234.
8. ®, a telemedical network to screen for diabetic retinopathy: a retrospective study in five reference hospital centres. Diabetes Metab 2009, 35:228-232.
9. Wilkinson C.P., Ferris F.L., Klein R.E., Lee L.P., Agardh C.D., Davis M., et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003, 110:1677-1682.
10. Cikamatana L., Mitchell P., Rochtchina E., Foran S., Wang J.J. Five years incidence and progression of diabetic retinopathy in a defined older population: the Blue Mountain Eye Study. Eye 2007, 21:465-471.
11. Tapp R.J., Tikellis G., Wong T.Y., Harper C.A., Zimmet P.Z., Shaw J.E. Longitudinal association of glucose metabolism with retinopathy: results from the Australian Diabetes Obesity and Lifestyle (AusDiab) Study. Diabetes Care 2008, 31:1349-1354.
12. McCarty D.J., Fu C.L., Harper C.A., Taylor H.R., McCarty C.A. Five-year incidence of diabetic retinopathy in the Melbourne Visual Impairment Project. Clin Exp Ophthalmol 2003, 31:397-402.
13. Younis N., Broadbent D.M., Vora J.P., Harding S.P. Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Eye Study: a cohort study. Lancet 2003, 361:195-200. Liverpool Diabetic Eye Study.
14. Younis N., Broadbent D.M., Harding S.P., Vora J.P. Incidence of sight-threatening retinopathy in type 1 diabetes in a systematic screening programme. Diabetic Med 2003, 20:758-765.
15. Chaturverdi N., Porta M., Klein R., Orchard T., Fuller J., Parving H.H., et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type-1 diabetes: randomized, placebo-controlled trials. Lancet 2008, 372:1394-1402.
16. ®: quality-assurance programme plan and performance of the network. Diabetes Metab 2008, 34:235-242.
17. Lane J.T. Microalbuminuria as a marker of cardiovascular and renal risk in type 2 diabetes mellitus: a temporal perspective. Am J Physiol Renal Physiol 2004, 286:442-540.
18. Stehouwer C., Nauta J., Zeldenrust G., Hackeng W., Donker A., Ottolander G. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in non-insulin-dependent diabetes mellitus. Lancet 1992, 340:319-323.
19. Cruisckshanks K.J., Ritter L.L., Klein R., Moss S.E. The association of microalbuminuria with diabetic retinopathy. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. Ophthalmology 1993, 100:862-867.
20. Manaviat M.R., Afkhami M., Shoja M.R. Retinopathy and microalbuminria in type 2 diabetic patients. BMC Ophthalmology 2004, 4:9.
21. Boetler M.C., Gross J.L., Canani L.H., Costa L.A., Lisboa H.R., Tres G.S., et al. Proliferative diabetic retinopathy is associated with microalbuminuria in patients with type 2 diabetes. Braz J Med Biol Res 2006, 39:1033-1039.